✦ LIBER ✦

Paclitaxel plus cisplatin and gemcitabine is `highly active' in patients with advanced urothelial tumours,

Book ID: 120867861
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2000
Weight: 134 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200012610-00029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacology of the paclitaxel–cisplatin

Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

✍ J. R. Kroep; E. F. Smit; G. Giaccone; K. Van der Born; J. H. Beijnen; C. J. Van 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 248 KB

Gemcitabine and paclitaxel chemotherapy

Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy

✍ Kunimitsu Kanai; Eiji Kikuchi; Takashi Ohigashi; Akira Miyajima; Ken Nakagawa; J 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 296 KB

Combination therapy with gemcitabine and

Combination therapy with gemcitabine and cisplatin is `highly active' and has `manageable toxicity' in patients with advanced transitional cell carcinoma

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

A multi-institutional phase II trial of

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

✍ Donald S. Kaufman; Michael A. Carducci; Tim M. Kuzel; Mary B. Todd; William K. O 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 63 KB

864 Combination of gemcitabine and pacli

864 Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy

✍ M. Ikeda; K. Matsumoto; K. Tabata; S. Minamida; T. Fujita; T. Satoh; M. Iwamura; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 16 KB

Pretreatment prognostic factors for surv

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

✍ Joaquim Bellmunt; Joan Albanell; Luis Paz-Ares; Miguel A. Climent; Jose L. Gonzá 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

## Background: New chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with these agents have shown promising results. unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplat